In yet another large recovery for the DOJ, on December 6, 2012, DFB Pharmaceuticals, and its subsidiary, Healthpoint Ltd., agreed as part of a settlement to pay up to $48 million to resolve allegations that Healthpoint caused false claims to be submitted to Medicare and Medicaid for an unapproved drug, Xenaderm.
http://www.jdsupra.com/legalnews/doj-recovers-up-to-48-million-in-false-51531/
http://www.jdsupra.com/legalnews/doj-recovers-up-to-48-million-in-false-51531/
No comments:
Post a Comment